远大医药(00512)股价绩前抢跑,尾盘涨幅扩大逾7%。截至发稿,涨6.92%,报8.96港元,成交额2.83亿港元。消息面上,远大医药拟于8月19日举行董事会会议批准中期业绩。公司近期宣布,公司全线放射性产品钇[90Y]微球注射液正式获得美国FDA批准新增适应症,用于治疗不可切除肝细胞癌(HCC),成为全球首个且唯一获FDA批准用于不可切除肝细胞癌和结直肠癌肝转移双重适应症的选择性内放射治疗产品...
Source Link远大医药(00512)股价绩前抢跑,尾盘涨幅扩大逾7%。截至发稿,涨6.92%,报8.96港元,成交额2.83亿港元。消息面上,远大医药拟于8月19日举行董事会会议批准中期业绩。公司近期宣布,公司全线放射性产品钇[90Y]微球注射液正式获得美国FDA批准新增适应症,用于治疗不可切除肝细胞癌(HCC),成为全球首个且唯一获FDA批准用于不可切除肝细胞癌和结直肠癌肝转移双重适应症的选择性内放射治疗产品...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.